Tseng, H., Dholaria, B., Cranert, S. A., Richter, M., Marquez, K. S., Cho, B. S., Bacong, A., McArthur, K., Eskew, J. D., McCaigue, J., Haag, S., Krasny, A., Solimine, B., Coffey, M. J., Loyola, A., Kwong, J., Shune, L., Kin, A., Costello, C. L., Kocoglu, M. H., Ramakrishnan, A., Namini, H., Martin, C. E., Belani, R., Coronella, J., Shedlock, D. J. (2025). TSCM-predominant allogeneic anti-BCMA CAR-T therapy for relapsed/refractory multiple myeloma: preclinical characterization and interim results from a phase 1 trial. Nature Communications. https://doi.org/10.1038/s41467-025-65267-0